USANA Health Sciences (NYSE:USNA) Releases Q3 2021 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its third quarter 2021 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.280-$1.330 for the period, compared to the Thomson Reuters consensus estimate of $1.440. The company issued revenue guidance of $265 million-$270 million, compared to the consensus revenue estimate of $303.24 million.USANA Health Sciences also updated its FY 2021 guidance to $5.800-$6.000 EPS.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised USANA Health Sciences from a sell rating to a hold rating in a research note on Wednesday, September 29th. Tigress Financial reaffirmed a buy rating and issued a $122.00 target price on shares of USANA Health Sciences in a research report on Friday, October 8th.

Shares of NYSE:USNA opened at $97.18 on Thursday. The company has a market cap of $1.94 billion, a P/E ratio of 14.66 and a beta of 0.85. The stock’s 50-day moving average is $94.42 and its 200-day moving average is $98.19. USANA Health Sciences has a 52-week low of $73.00 and a 52-week high of $107.85.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, July 27th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. USANA Health Sciences had a return on equity of 33.65% and a net margin of 11.09%. The business had revenue of $336.84 million for the quarter, compared to the consensus estimate of $340.20 million. Research analysts predict that USANA Health Sciences will post 6.31 EPS for the current fiscal year.

In other news, insider Robert A. Sinnott sold 1,648 shares of USANA Health Sciences stock in a transaction that occurred on Monday, August 16th. The shares were sold at an average price of $95.04, for a total value of $156,625.92. Following the completion of the transaction, the insider now owns 1,648 shares in the company, valued at $156,625.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 312 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, August 5th. The shares were sold at an average price of $96.52, for a total transaction of $30,114.24. The disclosure for this sale can be found here. Insiders have sold 3,435 shares of company stock worth $331,837 over the last ninety days. Company insiders own 0.21% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Further Reading: Investing in Blue-Chip Stocks

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with's FREE daily email newsletter.